October 18, 2007Open Access

Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The addition of rituximab to MPV increased the risk of significant neutropenia requiring routine growth factor support. Additional cycles of R-MPV nearly doubled the CR rate. Reduced-dose WBRT was not associated with neurocognitive decline, and disease control to date is excellent.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Shah et al. (Thu,) studied this question.

synapsesocial.com/papers/69d84d8ed2f7327e70ae2def https://doi.org/https://doi.org/10.1200/jco.2007.12.5062

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma2006 · 321 citations
2Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.2006 · 33 citations
3Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation therapy Oncology Group (RTOG): RTOG 83151992 · 636 citations
4Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers2004 · 26 citations
5Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.1986 · 167 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo